A. K. Ganguly

Distinguished Research Professor of Chemistry and Associate Director for Research

A.K. Ganguly joined Stevens in 1999 after more than 30 years of pharmaceutical industry research. He received his Ph.D. from Imperial College, London, and continued to work with his advisor, Sir Derek Barton, at the Research Institute of Medicine and Chemistry in Cambridge, Massachusetts. At Schering-Plough Research Institute, which he joined in 1968 as a senior scientist, Ganguly rose to the position of senior vice president of chemical research. He has served on the scientific boards of pharmaceutical companies and consulted with biotechnology companies internationally.

Many of his significant contributions are in drug discovery. He is associated with the discovery of Ezetimibe (Zetia), a cholesterol absorption inhibitor, Noxafil (Posaconazole), a potent antifungal, Boceprevir, a potent antiviral agent that inhibits HCY protease, and Lonafarnib (Sarasar), a highly selective farnesyl protein transferase inhibitor for the treatment of cancer. He is also recognized for his contributions toward synthesis of many other biologically active molecules and determining structures of several antibiotics which advanced to clinical trials.

Professor Ganguly is a co-author of more than 200 papers and is a co-inventor of 90 patents. He has been a plenary lecturer at many international meetings and received several awards. Some of his recent awards include the American Chemical Society (ACS) E.B. Hershberg Award, election to the ACS Hall of Fame, the Thomas Alva Edison Award, and a Lifetime Achievement Award from the Indian Chemical Society. In 2004, he received an honorary Doctor of Engineering degree from Stevens.

Areas of Expertise

•    Drug discovery/pharmaceutical research •    Design and synthesis of biologically active molecules

News Coverage

•    "Stevens' Dr. A. K. Ganguly receives Topliss Award Lecture from University of Michigan" - EurekAlert